undefined undefined
NaN.000
NaN.00%
In the preceding three months, 7 analysts have released ratings for AnaptysBio ...
05-11 05:01
AnaptysBio press release (NASDAQ:ANAB): Q1 GAAP EPS of -$1.64 misses by $0.04. Collaboration revenue was $7.2 million for the three months ended March 31, 2024, compared to $1.4 million for the three ...
05-10 05:53
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive ...
04-24 21:00
AnaptysBio(ANAB.US)获Leerink Partners首次覆盖,给予优于大市评级, 目标价47.00美元。
04-17 00:11
In the preceding three months, 4 analysts have released ratings for AnaptysBio ...
04-02 03:02
Gainers: Stoke Therapeutics (STOK) +87%. AnaptysBio (ANAB) +8%. Amneal Pharmaceuticals (AMRX) +6%. Omega Therapeutics (OMGA) +5%. MoneyHero (MNY) +5%. Losers: Ocular Therapeutix (OCUL) -6%. Fate Ther...
03-26 05:15
Wedbush analyst David Nierengarten upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Outperform.
03-12 19:11
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu,...
02-22 07:23
Demonstrates the Company's commitment to information securityOuster, Inc. (NYSE:OUST) ("Ouster" or the "Company"), a leading provider of high-performance lidar sensors, announced today that the Company achieved
2023-12-20 21:09